Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Clinical trial NCT05558722 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05558722
- Sponsor
- Xijing Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-05
- Primary completion
- 2024-08-15
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.